NEW YORK (GenomeWeb News) – PerkinElmer announced today that it has purchased several radiochemical-related reagent assets from GE Healthcare.

Under the agreement, PerkinElmer will obtain GE Healthcare's 3H and 14C catalog radiochemicals, along with its Scintillation Proximity Assay (SPA) reagents and Cytostar-T plate product lines.

Catalog radiochemicals are used for a variety of research purposes including binding assays that may reveal possible drug candidates. The SPA and Cytostar-T plate products, meanwhile, allow high-throughput screening for such interactions.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.